Methamphetamine Abuse Treatment in Patients With AIDS - 1

This study has been completed.

First Received on September 20, 1999. Last Updated on August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Friends Research Institute, Inc.
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000321

Purpose

The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.

Condition	Intervention	Phase
Substance-Related Disorders	Drug: Desipramine	Phase IV

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Methamphetamine Abuse Pharmacology in Patients With AIDS

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Depression Drug Abuse Methamphetamine

Drug Information available for: Desipramine Methamphetamine hydrochloride Desipramine hydrochloride Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Craving
Retention
Depression
Methamphetamine use
Anxiety and Depression
ASI Scales (7)
AIDS medical care engagement
High risk sexual behaviors
Mood indicators

Estimated Enrollment:	0
Study Start Date:	October 1996
Estimated Study Completion Date:	December 2001

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000321

Locations

United States, California
Friends Research Institute
Los Angeles, California, United States, 90025

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Friends Research Institute, Inc.

Investigators

Principal Investigator:

Frank Gawin, M.D.

Friends Research Institute, Inc.

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000321 History of Changes
Other Study ID Numbers:	NIDA-10643-1, R01-10643-1
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Substance-Related Disorders
Mental Disorders
Desipramine
Methamphetamine
Amphetamine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents

Therapeutic Uses
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Central Nervous System Stimulants
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on February 09, 2012